EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin) - Chemotherapy selected for multidrug resistance modulation

European Journal of Cancer

Volumn 38, Issue 18, 2002, Pages 2422-2427

  Davidson, A ^a   Dick, Gina ^a   Pritchard Jones, K ^b   Pinkerton, R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL ALEXANDRA CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cyclosporin; Epirubicin; Etoposide; Multi drug resistance; Reversal; Vincristine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; LORAZEPAM; ONDANSETRON; PARACETAMOL; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EWING SARCOMA; FEMALE; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; LIVER TOXICITY; MALE; MULTIDRUG RESISTANCE; NAUSEA; NEPHROBLASTOMA; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; ETOPOSIDE; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HEMATOLOGIC DISEASES; HUMAN; KIDNEY DISEASES; MALE; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; VINCRISTINE;

EID: 0036893565     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00493-8     Document Type: Article

References (22)

1. Ladenstein R., Hartmann O., Pinkerton C.R. The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol. 4:1993;45-58.
2. Vassal G, Pinkerton CR. Experimental therapeutics and new agents for neuroblastoma. In Brodeur GM, Sawada T, Tsuchida Y, Voute PA eds. Neuroblastoma. Elsevier Science, Amsterdam, 2000.
3. Lowis S.P., Newell D.R. Etoposide for the treatment of paediatric tumours. What is the best way to give it? Eur J Cancer. 32A:1996;2291-2297.
4. Phillips M.B., Pinkerton C.R. Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. Eur J Cancer. 28:1992;399-403.
5. Chamberlain M.C., Grafe M.R. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol. 13:1995;2072-2076.
6. Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC 833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 29A:1993;408-415.
7. Yanagisawa T., Newman A., Coley H.et al. BIRICODAR (VX-710): an effective chemosensitiser in neuroblastoma. Br J Cancer. 80:1999;1190-1196.
8. Cocker H.A., Pinkerton C.R., Kelland L.R. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br. J. Cancer. 83:2000;338-345.
9. Helson C., Zahn Z., Helson L. Reversion of P-glycoprotein mediated multi-drug resistance to vincristine and adriamycin by PSC-833, a cyclosporine derivative in human neuroblastoma cell lines. Int J Oncol. 5:1994;1037-1042.
10. Cairo M.S., Siegel S., Anas N., Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res. 49:1989;1063-1066.
11. Cowie F.J., Pinkerton C.R., Phillips M.et al. Continuous infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer. 71:1995;877-881.
12. Bisogno G., Cowie F., Boddy A., Thomas H.D., Dick G., Pinkerton C.R. High dose cyclosporin with etoposide - toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer. 77:1998;2304-2309.
13. Pinkerton C.R. Multidrug resistance in childhood solid tumours. Int J Pediat Hematol/Oncol. 4:1997;629-637.
14. Wilson W.H., Bates S.E., Fojo ATet al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol. 8:1995;1995-2004.
15. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 9:1991;17-24.
16. Dalton W.S., Crowley J.J., Salmon S.S., Grogan T.M., Laufman L.R., Weiss G.R., Bonnet J.D. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. J Clin Oncol. 75:1995;815-820.
17. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Cancer. 68:1993;813-818.
18. Tidefelt U., Liliemark J., Gruber A.et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukaemia. J Clin Oncol. 18:2000;1937-1944.
19. Fracasso P.M., Brady M.F., Moore D.H.et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 19:2001;2975-2982.
20. Baekelandt M., Lehne G., Trope C.G.et al. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol. 19:2001;2983-2993.
21. Rowinsky E.K., Smith L., Wang Y.M.et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 16:1998;2964-2976.
22. Muzzammil T., Moore M.J., Hedley D., Ballinger J.R. Comparison of (99m) Tc-sestamibi and doxorubicin to monitor inhibition of p-glycoprotein function. Br J Cancer. 84:2001;367-373.